Heart Failure With Normal Ejection Fraction Clinical Trial
Official title:
Cross-sectional Observational Single-center Study to Evaluate Renal Hemodynamics in Patients With Heart Failure and Preserved Ejection Fraction
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two
often co-existing medical conditions and are known to be associated with adverse
cardiovascular outcome and increased mortality. The relationship between HFpEF and renal
impairment is bidirectional. On the one hand, renal dysfunction has been shown to be an
independent risk factor for the development of HFpEF. On the other hand, an increase in
central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF)
and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone
system (RAAS) in patients with HFpEF has been previously described.
In the literature, several studies aimed to investigate the association between renal (dys-)
function and HFpEF. In all these studies, renal function was assessed by determination of
standard kidney function parameters such as serum creatinine, eGFR and urinary albumin to
creatinine ratio (UACR). Constant infusion input clearance technique however offers a more
detailed evaluation of renal function and hemodynamics. To the best of knowledge, renal
hemodynamics in patients with HFpEF have not yet been investigated by clearance technique.
Therefore, the aim of the present study is to evaluate renal function and hemodynamics by
means of constant infusion input clearance technique with sodium p-aminohippuric acid (PAH)
and Iohexol in 40 patients with HFpEF. The constant infusion input clearance technique offers
an exact evaluation of renal function by measuring (not estimating) glomerular filtration
rate and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction
(FF) and intraglomerular pressure (IGP). These results will be compared to 140 subjects
without HFpEF that have participated in various studies and have been analyzed with the same
constant infusion input clearance technique performed in the Clinical Research Center of the
University Hospital Erlangen-Nuremberg. Additionally, flow mediated vasodilation (FMD), pulse
wave velocity and parameters of retinal vascular remodeling by means of scanning laser
Doppler flowmetry (SLDF) will be assessed in patients with HFpEF thereby allowing to examine
the relationship between vascular remodeling in the systemic and renal circulation.
Several studies evaluating the outcome among patients with HFpEF revealed that this entity of
heart failure (HF) is associated with high mortality rates and some studies even indicate
that mortality is similar to patients with heart failure and reduced ejection fraction
(HFrEF). Hospitalization for HFpEF is increasing relative to HFrEF, highlighting the need for
a better understanding of the pathogenetic processes in order to develop new treatment
strategies for this type of HF. Recently, the PARAMOUNT study revealed that in patients with
HFpEF, treatment with the dual-acting angiotensin receptor neprilysin inhibitor (ARNI) LCZ696
was associated with lower levels of creatinine and higher estimated glomerular filtration
rates (eGFR) indicating a better preservation of renal function in comparison to treatment
with valsartan only. Another observation of this study was an increase in urinary albumin to
creatinine ratio (UACR) in the group of LCZ696-treatment, which was not visible in patients
randomized to the valsartan group. Additionally, analysis of the relation between albuminuria
and/or decreased eGFR and cardiovascular function and structure revealed that renal
dysfunction was common in this group of patients and associated with cardiac remodeling and
dysfunction.
Up to two thirds of patients with HFpEF are suffering from chronic kidney disease (CKD). A
bidirectional cardiorenal relation has been recently described and is known to be associated
with adverse cardiovascular outcome and increased mortality. On the one hand, renal
dysfunction has been shown to be an independent risk factor for the development of HFpEF due
to inflammatory processes and endothelial dysfunction. On the other hand, an increase in
central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF)
and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone
system (RAAS) in patients with HFpEF has been previously described.
This association has also been demonstrated for patients with HFrEF. However, several studies
comparing patients with the two subtypes of HF in the context of CKD indicate that this
association is more pronounced in patients with HFpEF. For example, a community-based cohort
study by Brouwers et al. including 8592 subjects of the PREVEND trial showed that renal
function parameters such as urinary albumin excretion (UAE) and cystatin C were associated
with a high risk for the development of HFpEF but not HFrEF. Ahmed et al. even reported a
higher CKD-related mortality in HFpEF than in HFrEF patients with an underlying
graded-response relation as CKD-associated mortality increased with higher left ventricular
ejection fraction (LVEF). These findings suggest different pathogenetic processes for these
two subtypes of HF. Therefore, detailed exploration of the pathophysiological mechanisms
behind the relationship of HFpEF and renal function represents a matter of major research
interest.
Recently, several studies aimed to investigate the association between renal (dys-) function
and HFpEF. Unger et al. retrospectively examined the relationship between renal function and
echocardiographic parameters in 299 patients with HFpEF. The analysis revealed that CKD was
independently associated with worse cardiac mechanics and outcomes in this population.9
Studying 217 participants from the PARAMOUNT trial with HFpEF, Gori et al. demonstrated that
renal dysfunction was associated with abnormal left ventricular geometry, lower midwall
fractional shortening and higher NT-proBNP. In both studies, renal function was assessed with
commonly used tests such as determination of serum creatinine, eGFR and urinary albumin to
creatinine ratio (UACR). However, these parameters only allow an approximate estimation of
renal function. Constant infusion input clearance technique offers a more complete approach
towards evaluation of renal function and perfusion, allowing an exact quantification of
glomerular filtration rate (GFR) and renal hemodynamic parameters such as renal plasma flow
(RPF), filtration fraction (FF) and intraglomerular hemodynamics.
The definition of HFpEF in literature is rather inconsistent. In some studies, HFpEF was
defined by an ejection fraction of ≥ 45%, whereas other authors used a cut-off value of 50%.
In the present study, the categorization of heart failure as HFpEF will follow the 2016
European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and
chronic heart failure applying a cut-off value of 50%.
The purpose of the present study is to evaluate renal function and hemodynamics by means of
constant infusion input clearance technique with PAH and Iohexol in 40 patients with HFpEF
with the aim to better characterize the relationship between renal dysfunction and HFpEF.
These results will be compared to 140 subjects without HFpEF who participated in different
studies during which renal clearance examination has been performed with the constant
infusion input clearance technique in the Clinical Research Center of the University Hospital
Erlangen-Nuremberg. In parallel, pulse wave velocity, flow mediated vasodilation and other
vascular parameters, reflecting the vascular wall properties of small and large arteries,
will be assessed. Additionally, there will be a non-invasive retinal examination to assess
vascular remodeling of retinal arterioles (wall to lumen ratio, WLR), retinal capillary flow
(RCF) and capillary rarefaction.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT02459626 -
Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction
|
||
Completed |
NCT02173548 -
Interleukin-1 Blockade in HF With Preserved EF
|
Phase 2 | |
Completed |
NCT03310099 -
Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients
|
N/A | |
Completed |
NCT02638961 -
Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF
|
N/A | |
Completed |
NCT03871803 -
β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)
|
Phase 4 | |
Recruiting |
NCT03620526 -
Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction
|
Phase 4 | |
Active, not recruiting |
NCT03624010 -
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
|
Phase 2 | |
Completed |
NCT03541603 -
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
|
Phase 2 | |
Completed |
NCT03141567 -
LYmphangiogenesis FacTors in Heart Failure States
|
||
Completed |
NCT02744339 -
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Completed |
NCT03387813 -
Hemodynamic-GUIDEd Management of Heart Failure
|
N/A | |
Completed |
NCT03186833 -
The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.
|
||
Completed |
NCT03289481 -
Treatment of HFpEF With Nitrate Supplement
|
Early Phase 1 | |
Terminated |
NCT03195660 -
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
|
N/A | |
Completed |
NCT03226652 -
Heart Function in Patients Assessed for Sleep Apnoea
|
||
Completed |
NCT03966755 -
Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Obesity and HFpEF
|
N/A | |
Not yet recruiting |
NCT04282850 -
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF
|
N/A | |
Recruiting |
NCT03184311 -
High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction
|
N/A | |
Withdrawn |
NCT03317314 -
Cardiopulmonary Interactions in Patients With Heart Failure
|